Cargando…

EZH2 in Bladder Cancer, a Promising Therapeutic Target

Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the pathogenesis of these tumors. Among the epigenetic alterations, histone modifications occupied a ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Fernández, Mónica, Rubio, Carolina, Segovia, Cristina, López-Calderón, Fernando F., Dueñas, Marta, Paramio, Jesús M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661858/ https://www.ncbi.nlm.nih.gov/pubmed/26580594 http://dx.doi.org/10.3390/ijms161126000

Ejemplares similares

Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer
por: Segovia, Cristina, et al.
Publicado: (2017)

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
por: Martinez, Victor G., et al.
Publicado: (2019)

CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
por: Lodewijk, Iris, et al.
Publicado: (2023)

Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer
por: Martínez-Fernández, Mónica, et al.
Publicado: (2015)

Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring
por: Lodewijk, Iris, et al.
Publicado: (2018)

A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
por: Martínez-Fernández, Mónica, et al.
Publicado: (2015)

DNA Methylation as a Therapeutic Target for Bladder Cancer
por: Nunes, Sandra P., et al.
Publicado: (2020)

lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
por: Wozniak, Michal, et al.
Publicado: (2023)

Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
por: Dueñas, Marta, et al.
Publicado: (2019)

Androgen receptor in bladder cancer: A promising therapeutic target
por: Tripathi, Abhishek, et al.
Publicado: (2020)

c-Met: A Promising Therapeutic Target in Bladder Cancer
por: Feng, Yanfei, et al.
Publicado: (2022)

Cell Therapies in Bladder Cancer Management
por: Morales, Lucia, et al.
Publicado: (2021)

EZH2: novel therapeutic target for human cancer
por: Li, Long-Yuan
Publicado: (2014)

The downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior
por: Bornachea, Olga, et al.
Publicado: (2015)

EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target
por: Lin, Zhuangling, et al.
Publicado: (2023)

Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies
por: Carvalho, Sandra, et al.
Publicado: (2020)

EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells
por: Zhang, Xiangyan, et al.
Publicado: (2021)

Regulation of TRAIL expression by PRAME and EZH2 as potential therapeutic target against solid tumors
por: Mello, Barbara P, et al.
Publicado: (2013)

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018)

Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases
por: Li, Tingting, et al.
Publicado: (2021)

EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine
por: Barazeghi, Elham, et al.
Publicado: (2021)

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?
por: Ding, Shu, et al.
Publicado: (2022)

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
por: Ciarapica, Roberta, et al.
Publicado: (2014)

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013)

Toward Tumor Fight and Tumor Microenvironment Remodeling: PBA Induces Cell Cycle Arrest and Reduces Tumor Hybrid Cells’ Pluripotency in Bladder Cancer
por: Rubio, Carolina, et al.
Publicado: (2022)

Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
por: Lodewijk, Iris, et al.
Publicado: (2021)

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target
por: Li, Hua, et al.
Publicado: (2013)

The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
por: Li, Zhongwu, et al.
Publicado: (2013)

Targeting EZH2 as a novel therapeutic strategy for sorafenib‐resistant thyroid carcinoma
por: Wang, Zhengshi, et al.
Publicado: (2019)

Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer
por: Hu, Jilong, et al.
Publicado: (2021)

Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?
por: Cosín-Roger, Jesús, et al.
Publicado: (2020)

Functional and therapeutic significance of EZH2 in urological cancers
por: Liu, Xiaobing, et al.
Publicado: (2017)

Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer
por: Loras, Alba, et al.
Publicado: (2019)

Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo
por: Tang, Shou-Hung, et al.
Publicado: (2014)

MEK is a promising target in the basal subtype of bladder cancer
por: Merrill, Nathan M., et al.
Publicado: (2020)

miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer
por: Cai, Zhonglin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_395viv8r4lmq9o7okub95ru5ve